Dual blocking PD-1 and Tim-3 not only on T cells but also on DC, NK cells may achieve better clinical benefit. LB1410 is a recombinant humanized anti-PD-1/TIM-3 bispecific antibody (BsAb) developed by ...

This material on this page is ©2025 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please ...

The regeneration-infiltration step was repeated 3 times. Data analysis 7.0 software was used to analyze the affinity of antibody samples. BLI analysis of the binding activity of YG-003D3 to PD-1/LAG-3 ...

Agenus (AGEN) entered into a License, Development, and Commercialization Agreement with Incyte (INCY), under which Incyte ...

A team of researchers have made a new discovery in the field of hematology, providing an explanation for spontaneous and ...

Breastfeeding not only caters to a baby's nutritional needs, it also helps it bond with the mother. Paediatrician shares tips ...

Adding the anti-CD20 monoclonal antibody obinutuzumab (Gazyva) to standard therapy for lupus nephritis is more efficacious ...

GSK has news on that front today, as well, reporting that the phase 2/3 COSTAR trial of Jemperli with experimental TIM-3 antagonist cobolimab will move into the phase 3 stage on the advice of its ...